Systemic or regional chemotherapy: does it matter and should surgeons be involved?
TNF (tumour necrosis factor) is a new immunological anti-cancer agent which is too toxic for systemic use and relatively ineffective when used alone, but remarkably effective when used in closed circuit perfusion techniques together with other anti-cancer agents. Several studies have shown that when TNF is used with melphalan in closed circuit perfusion treatment for multiple melanoma metastases confined to a limb, a response rate of 80% can be achieved compared to a best response rate of 40% with melphalan alone. These findings confirm the difference in tumour responses which can be achieved with the appropriate use of regional chemotherapy in treatment of locally advanced tumours and the importance of surgical oncologists and vascular radiologists in maintaining and developing skills in integrated regional cancer treatment.
Stephens
F O
FO
Sydney Melanoma and Surgical Oncology Unit, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
D010478:Chemotherapy, Cancer, Regional Perfusion; D006801:Humans; D008545:Melanoma / Q000188:drug therapy; D008558:Melphalan / Q000008:administration & dosage; D009369:Neoplasms / Q000628:therapy; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan